Cited by 449Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesChild and Adolescent Psychosocial and Emotional Development

Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression

Open access
McMakin, Dana L., Olino, Thomas M., Porta, Giovanna, Dietz, Laura J., Emslie, Graham, Clarke, Gregory, Wagner, Karen Dineen, Asarnow, Joan R. +10 more·2012·Journal of the American Academy of Child & Adolescent Psychiatry

Abstract

Objective To identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (SSRI) treatment-resistant adolescents undergoing second-step treatment.Method The Treatment of Resistant Depression in Adolescents (TORDIA) trial included 334 SSRI treatment-resistant youth randomized to a medication switch, or a medication switch plus CBT. This study examined five established symptom dimensions (Child Depression Rating Scale-Revised) at baseline as they predicted recovery over 24 weeks of acute and continuation treatment. The two indices of recovery that were evaluated were time to remission and number of depression-free days.Results Multivariate analyses examining all five depression symptom dimensions simultaneously indicated that anhedonia was the only dimension to predict a longer time to remission, and also the only dimension to predict fewer depression-free days. In addition, when anhedonia and CDRS-total score were evaluated simultaneously, anhedonia continued to uniquely predict longer time to remission and fewer depression-free days.Conclusions Anhedonia may represent an important negative prognostic indicator among treatment-resistant depressed adolescents. Further research is needed to elucidate neurobehavioral underpinnings of anhedonia, and to test treatments that target anhedonia in the context of overall treatment of depression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaac.2012.01.011

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Anhedonia is a negative prognostic factor for treatment outcome in adolescents and adults.

    “Furthermore, it was shown that anhedonia is a negative prognostic factor for treatment outcome both in adolescents (McMakin et al., 2012) and adults (Spijker et al., 2001; Vrieze et al., 2014).”

    From Circuit Mechanisms of Reward, Anhedonia, and Depression (2019) · cites this paper as McMakin et al., 2012

  • Anhedonia typically does not respond to first-line pharmacotherapies.

    “Anhedonia typically does not respond to first-line pharmacotherapies [5, 7, 8]”
  • Persistent, trait-like social anhedonia in early adolescence predicts increased severity of, and poorer recovery from, depression, above and beyond other illness features.

    “Indeed, persistent, trait-like social anhedonia in early adolescence predicts increased severity of, and poorer recovery from, depression, above and beyond other illness features (184)”

    From A transdiagnostic perspective on social anhedonia (2019) · cites this paper as [184]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
McMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., Shamseddeen, W., Mayes, T., Kennard, B., Spirito, A., Keller, M., Lynch, F. L., Dickerson, J. F., & Brent, D. A.
Affiliations
  • University of Pittsburgh (US)
  • The University of Texas Southwestern Medical Center (US)
  • Kaiser Permanente (US)
  • The University of Texas Medical Branch at Galveston (US)
  • University of California, Los Angeles (US)
  • Rosalind Franklin University of Medicine and Science (US)
  • Brown University (US)
Corresponding author
McMakin, Dana L.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2012-04
Volume
51
Issue
4
Pages
404-411
ISSN
0890-8567 (ISSN-L)
OpenAlex
W2065796254
Cited by
448
References
37
Citations by year
2026: 23 · 2025: 50 · 2024: 52 · 2023: 33 · 2022: 45 · 2021: 53 · 2020: 39 · 2019: 41 · 2018: 23 · 2017: 18 · 2016: 18 · 2015: 17 · 2014: 23 · 2013: 11 · 2012: 2
FWCI
12.45
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Health and Human Services
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Kaiser Permanente
  • University of Pittsburgh
  • Melissa Institute for Violence Prevention and Treatment
  • Valeant Pharmaceuticals International
  • Rosalind Franklin University of Medicine and Science
  • H. Lundbeck A/S
  • National Institutes of Health
  • University of California, Los Angeles (MH61958, MH66371, MH61869, MH62014)
  • National Institute of Mental Health (MH61958, U01MH061856, MH-66371, U01MH061835, U01MH061869, MH-61869, U01MH062014, K01MH092603, MH61856, MH-61835, MH61864, K23MH092400, U01MH061958, P30MH066371, T32MH018951, U01MH061864, MH62014)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
anhedonia, treatment-resistant depression, adolescent depression, selective serotonin reuptake inhibitors, prognostic factors, remission, cognitive behavioral therapy
MeSH terms
Venlafaxine Hydrochloride, Adolescent, Affect, Combined Modality Therapy, Cyclohexanols, Major Depressive Disorder, Double-Blind Method, Drug Resistance, Female, Humans, Longitudinal Studies, Male, Personality Assessment, Psychometrics, Psychotherapy, Cognitive Behavioral Therapy, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Drug Substitution, Anhedonia, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review